WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

EMA

The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.

www.ema.europa.eu

EMA RSS Channel

Filters
List of articles in category EMA
Title Published Date
EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice 31 March 2022
EMA: Human medicines highlights of 2021 18 February 2022
ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines 06 September 2021
AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 07 April 2021
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna 29 March 2021
EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events 15 March 2021
EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU 11 March 2021
EMA starts rolling review of the Sputnik V COVID-19 vaccine 08 March 2021
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca 12 January 2021
Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application 15 December 2020
EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2 01 December 2020
EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine 01 December 2020
EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation 30 September 2020
Global regulators commit to cooperate on observational research in the context of COVID-19 21 May 2020
First vaccine to protect against Ebola 28 October 2019
EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US 29 August 2019
EMA to relocate to Amsterdam, the Netherlands 22 November 2017
Green light given for new EudraVigilance system for collection and monitoring of suspected adverse reactions 29 May 2017
Launch of PRIME - Paving the way for promising medicines for patients 10 March 2016
Human medicines: highlights of 2015 22 January 2016
  • Start
  • Prev
  • 1
  • 2
  • 3
  • Next
  • End
Tahmeena

Business & Industry

  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed
  • Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
  • NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs

Research & Development

  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic
  • Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. EMA

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.